HJC黄金城官方网站

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has successfully completed the acquisition of F-star Therapeutics, Inc. (“F-star”) (NASDAQ: FSTX) a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share).

On February 20, Sino Biopharm (HKE.01177) announced that Liamprost tablet (brand name: Kelitone ?), a treatment for lumbar spinal stenosis developed by its subsidiary of Beijing Tide, has been approved by the National Medical Products Administration (NMPA). Miss Tse, Theresa Y Y, chairwoman of the board of directors of Sino Biopharm, said dealing with an aging population has been elevated as a national strategy in the 2022 Government Work

On February 10, Sino Biopharm announced that its self-developed Class 1 new drug, TQB2103 (Claudin18.2 ADC), has submitted an application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration, PRC for clinical trials and has been accepted.

On January 29th, Sino Biopharm and its subsidiary CTTQ signed an investment framework agreement with the Administrative Committee of Guangzhou Development Zone to invest in the construction of the Southern headquarters and overseas pharmaceutical innovation center in the area. Lin Keqing, Party Secretary of Guangzhou Municipality, Guo Yonghang, Mayor of Guangzhou Municipality,